COVID-19 spike-ACE2 binding assay for drug and antibody screening
US11105804B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 5, 2021 |
| Grant date | Aug 31, 2021 |
| Priority date | — |
| Expiry date | Jan 5, 2041 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/20
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present disclosure an ELISA-based assay that uses a glycosylated polypeptide fragment derived from the SARS-CoV-2 spike protein (Covid-19) receptor binding domain (S1RBD) that has affinity for the extracellular domain of Angiotensin Converting Enzyme 2 (ACE2). The S1RBD polypeptide is generated by expression of an encoding nucleic acid by a human cell expression system resulting in glycosylation of the expressed spike receptor binding domain (S1RBD) protein at least at the N343 N-glycosylation site thereof, and which surprisingly and significantly increases the affinity of the S1RBD for ACE2, provides a significant increase in the sensitivity of the assay compared to other known assays.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.